Last reviewed · How we verify
NVR 3-778
At a glance
| Generic name | NVR 3-778 |
|---|---|
| Sponsor | Novira Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients (PHASE1)
- Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients (PHASE1)
- Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVR 3-778 CI brief — competitive landscape report
- NVR 3-778 updates RSS · CI watch RSS
- Novira Therapeutics, Inc. portfolio CI